NCT02403778View on ClinicalTrials.gov

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

January 18, 2023

Conditions
Melanoma
Interventions
DRUG

VESANOID

All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).

DRUG

Ipilimumab

Ipilimumab is current standard of care treatment for melanoma.

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02403778 - Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | Biotech Hunter | Biotech Hunter